Premium
Ulcerated Infantile Hemangioma: Novel Treatment with Topical Brimonidine‐Timolol
Author(s) -
Beal Brandon T.,
Chu Melinda B.,
Siegfried Elaine C.
Publication year - 2014
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.12420
Subject(s) - brimonidine , timolol , medicine , infantile hemangioma , hemangioma , lesion , dermatology , agonist , ophthalmology , anesthesia , intraocular pressure , surgery , receptor
We report a 2‐month‐old boy with a painful ulcerated hemangioma on the lower mucosal lip extending to the vermillion border that caused feeding difficulty. It was successfully treated with topical brimonidine 0.2% and timolol 0.5%, a combination selective α 2 ‐adrenergic agonist and nonselective β‐blocker. After 6 weeks of treatment, the lesion reepithelialized and the patient's symptoms and functional complications resolved. Brimonidine 0.2% timolol 0.5% ophthalmic solution is an emerging alternative treatment for hemangiomas, offering the potential to target hemangioma growth through two synergistic mechanisms (β‐inhibition and α 2 ‐agonism) that may be especially effective for ulcerated lesions, the most common complication of infantile hemangiomas.